#ABCHCC - Twitter Hashtag

about 2 months ago

We can do better in 2026. #ASCO26 #EMERALD3 #EMERALD1 #CM74W #CHECKMATE74W #LEAP012 #TACE3 #RENOTACE #ABCHCC #OncTwitter #HCC #LiverTwitter #GITwitter

Jeff Ryckman

@jryckman3

2 months ago

At some point, we have to ask whether continuing to build large phase III trials on a local therapy backbone with ~40 to 60% failure is the best use of resources. Positive PFS is not surprising when LC is the weak link. We can do better in 2026. #ASCO26 #OncTwitter #LiverTwitter #HCC #GITwitter #EMERALD3

jryckman3's tweet photo. At some point, we have to ask whether continuing to build large phase III trials on a local therapy backbone with ~40 to 60% failure is the best use of resources.

Positive PFS is not surprising when LC is the weak link.

We can do better in 2026.

#ASCO26 #OncTwitter #LiverTwitter #HCC #GITwitter #EMERALD3

1

36

11

2

7K

0

3

0

757

Jeff Ryckman

@jryckman3

about 1 year ago

@5_utr Great way to design a “positive” systemic therapy trial: use TACE as the LC backbone 🙄 #LEAP012 #EMERALD1 #CheckMate74W #TACE3 #RENOTACE #ABCHCC Only real takeaway from these trials? “The money was spent.”

jryckman3's tweet photo. @5_utr Great way to design a “positive” systemic therapy trial: use TACE as the LC backbone 🙄 #LEAP012 #EMERALD1 #CheckMate74W #TACE3 #RENOTACE #ABCHCC

Only real takeaway from these trials? “The money was spent.” https://t.co/0KpjG4ZodB

1

8

1

2

770

Jeff Ryckman

@jryckman3

over 2 years ago

@KolPulseAI @pashtoonkasi @BeauToskichMD @GABOUALFA @rachnatshroff #EMERALD1 #CHECKMATE74W #LEAP012 #TACE3 #RENOTACE #ABCHCC Should these trials show an OS benefit, it's likely because of 📈LF rates s/p TACE. The key hurdle in treating inoperable #HCC is showing an OS benefit for systemic tx when LC ≥ 85% (e.g., SBRT) https://t.co/s1OrVp6lVg

Jeff Ryckman

@jryckman3

over 2 years ago

🚨#EMERALD1 represents just a tiny portion of ongoing trials examining TACE in combo with immunotherapy. Additional studies underway: #CHECKMATE74W, #LEAP012, #TACE3, #RENOTACE, & #ABCHCC. ⚠️Achieving a 40-50% rate of LC in #HCC in 2024 is unacceptable. #LiverTwitter #radonc

jryckman3's tweet photo. 🚨#EMERALD1 represents just a tiny portion of ongoing trials examining TACE in combo with immunotherapy.

Additional studies underway: #CHECKMATE74W, #LEAP012, #TACE3, #RENOTACE, & #ABCHCC.

⚠️Achieving a 40-50% rate of LC in #HCC in 2024 is unacceptable.

#LiverTwitter #radonc https://t.co/hL7J6Y38V9

1

34

11

19K

0

2

0

622

Jeff Ryckman

@jryckman3

over 2 years ago

🚨#EMERALD1 represents just a tiny portion of ongoing trials examining TACE in combo with immunotherapy. Additional studies underway: #CHECKMATE74W, #LEAP012, #TACE3, #RENOTACE, & #ABCHCC. ��️Achieving a 40-50% rate of LC in #HCC in 2024 is unacceptable. #LiverTwitter #radonc

1

34

11

19K

Top Tweets for #ABCHCC

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users